Status:
COMPLETED
Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer
Lead Sponsor:
SCRI Development Innovations, LLC
Collaborating Sponsors:
Celgene Corporation
Conditions:
Metastatic Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
This is a retrospective medical record abstraction study. It is a review and evaluation of up to 300 metastatic breast cancer patients treated with Abraxane or other taxanes such as paclitaxel and doc...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients that have received Abraxane chemotherapy greater than three months from the time of chart review.
- Patients that have received taxane chemotherapy greater than three months from the time of chart review.
Exclusion
Key Trial Info
Start Date :
November 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2011
Estimated Enrollment :
198 Patients enrolled
Trial Details
Trial ID
NCT00876070
Start Date
November 1 2008
End Date
February 1 2011
Last Update
November 21 2011
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Georgia Cancer Specialists
Atlanta, Georgia, United States, 30341
2
Tennessee Oncology, PLLC
Nashville, Tennessee, United States, 37023